Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (151-160 of 436) with videos related to

Pageof 44
Sort By:
Haematologica|November 6, 2025
Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1Valerio Ciaurro, Vassilena Sharlandjieva, Anna Skwarska, et al.
Cancer|October 23, 2025
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lensHagop M Kantarjian, Gautam Borthakur, Naval Daver, et al.
American Journal of Hematology|October 14, 2017
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitorsAhmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, et al.
Leukemia & Lymphoma|September 6, 2013
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapsePreetesh Jain, Hagop Kantarjian, Keyur Patel, et al.
Leukemia & Lymphoma|August 19, 2025
Mortality and relapse dynamics in AML after three years of complete remissionSamuel Urrutia, Wei-Ying Jen, Koji Sasaki, et al.
Cancer Research Communications|February 23, 2024
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade TherapyJessica L Root, Poonam N Desai, Christopher Ly, et al.
Cancer|August 11, 2016
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phaseKoichi Takahashi, Hagop M Kantarjian, Yulong Yang, et al.
Cancer|October 20, 2015
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Preetesh Jain, et al.
American Journal of Hematology|December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromePaolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, James S Blachly, Armin Ghobadi, et al.
Pageof 44

Showing results (151-160 of 436) with videos related to

Sort By:
Pageof 44
Haematologica|November 6, 2025
Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1Valerio Ciaurro, Vassilena Sharlandjieva, Anna Skwarska, et al.
Cancer|October 23, 2025
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lensHagop M Kantarjian, Gautam Borthakur, Naval Daver, et al.
American Journal of Hematology|October 14, 2017
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitorsAhmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, et al.
Leukemia & Lymphoma|September 6, 2013
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapsePreetesh Jain, Hagop Kantarjian, Keyur Patel, et al.
Leukemia & Lymphoma|August 19, 2025
Mortality and relapse dynamics in AML after three years of complete remissionSamuel Urrutia, Wei-Ying Jen, Koji Sasaki, et al.
Cancer Research Communications|February 23, 2024
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade TherapyJessica L Root, Poonam N Desai, Christopher Ly, et al.
Cancer|August 11, 2016
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phaseKoichi Takahashi, Hagop M Kantarjian, Yulong Yang, et al.
Cancer|October 20, 2015
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Preetesh Jain, et al.
American Journal of Hematology|December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromePaolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, James S Blachly, Armin Ghobadi, et al.
Pageof 44